Click here to view the Humana Medical Policy Updates Updates » September 2024 Humana Medical…
Humana January 2018 Pharmacy Policy Updates
Click here to view the Humana Pharmacy Policy Updates »
January 2018 Pharmacy Policy Updates
| Policy Name | Reviewed Date |
| ADHD Long Acting Stimulants | 1/17/2018 |
| Aggrenox® (aspirin/dipyridamole) | 1/17/2018 |
| Alecensa® (alectinib) | 1/17/2018 |
| Allergy Ophthalmics | 1/17/2018 |
| Aloxi® (palonosetron) | 1/17/2018 |
| Alphagan® P (brimonidine) | 1/17/2018 |
| AmBisome® (amphotericin B liposome) | 1/17/2018 |
| Aranesp® (darbepoetin alfa) | 1/17/2018 |
| Asthma Interleukin Inhibitors (Cinqair, Nucala, Fasenra) | 1/17/2018 |
| AzaSite® (azithromycin ophthalmic solution) | 1/17/2018 |
| Betaseron® [interferon beta-1b] | 1/17/2018 |
| Bowel Prep Agents | 1/17/2018 |
| Bowel Prep Agents | 1/17/2018 |
| Buprenorphine Containing Products | 1/17/2018 |
| Calquence® (acalabrutinib) | 1/17/2018 |
| Caprelsa® (vandetanib) | 1/17/2018 |
| Cervarix® (human papillomavirus bivalent vaccine) | 1/17/2018 |
| Cinvanti (aprepitant) | 1/17/2018 |
| Cometriq® (cabozantinib) | 1/17/2018 |
| Corticosteroid and Long Acting Beta Agonist Combination Inhalers | 1/17/2018 |
| Cosentyx® (secukinumab) | 1/17/2018 |
| Cosopt® (dorzolamide and timolol ophthalmic solution) | 1/17/2018 |
| Cresemba® (isavuconazonium sulfate) | 1/17/2018 |
| Dextroamphetamine/amphetamine extended release | 1/17/2018 |
| Dificid® (fidaxomicin) | 1/17/2018 |
| Dysport® (Botulinum Toxin) | 1/17/2018 |
| Eligard® (leuprolide acetate) | 1/17/2018 |
| Firmagon® (degarelix) | 1/17/2018 |
| Gardasil® (human papillomavirus vaccine) | 1/17/2018 |
| Gilenya® (fingolimod) | 1/17/2018 |
| Influenza Virus Vaccine | 1/17/2018 |
| Intranasal Rhinitis Agents | 1/17/2018 |
| Intuniv® (guanfacine extended-release tablets) | 1/17/2018 |
| Kapvay® (extended-release clonidine) | 1/17/2018 |
| Lemtrada® (alemtuzumab) | 1/17/2018 |
| Leuprolide acetate | 1/17/2018 |
| Lidoderm® (lidocaine 5% patch) | 1/17/2018 |
| Lonsurf® (trifluridine and tipiracil) | 1/17/2018 |
| Lupron® (leuprolide acetate) | 1/17/2018 |
| Mirvaso® (brimonidine topical gel) | 1/17/2018 |
| Myobloc® (Botulinum Toxin) | 1/17/2018 |
| Non-Sedating Antihistamines | 1/17/2018 |
| Noxafil® (posaconazole) | 1/17/2018 |
| Nulojix® (belatacept) | 1/17/2018 |
| Onivyde ® (liposomal irinotecan) | 1/17/2018 |
| Ophthalmic Antibiotics | 1/17/2018 |
| Ophthalmic Beta Blockers | 1/17/2018 |
| Ophthalmic Steroids | 1/17/2018 |
| Ophthalmic Steroids | 1/17/2018 |
| Portrazza™ (necitumumab) | 1/17/2018 |
| Portrazza™ (necitumumab) | 1/17/2018 |
| Qualaquin® (quinine sulfate) | 1/17/2018 |
| Quillivant XR® (methylphenidate hydrochloride) | 1/17/2018 |
| Radicava™ (edaravone) | 1/17/2018 |
| Ravicti® (glycerol phenylbutyrate) | 1/17/2018 |
| Rebif® (interferon beta-1a) | 1/17/2018 |
| Rhofade™ (oxymetazoline) cream | 1/17/2018 |
| Shingrix (zoster vaccine recombinant, adjuvanted) | 1/17/2018 |
| Sirturo® (bedaquiline) | 1/17/2018 |
| Sitavig® (acyclovir) | 1/17/2018 |
| Solaraze® (diclofenac) | 1/17/2018 |
| Soriatane® (acitretin) | 1/17/2018 |
| Strattera® (atomoxetine) | 1/17/2018 |
| Sublingual Allergen Extract | 1/17/2018 |
| Synagis® (palivizumab) | 1/17/2018 |
| Topical Metronidazole | 1/17/2018 |
| Topical Onychomycotic Agents (Jublia® and Kerydin®) | 1/17/2018 |
| Trelstar® (triptorelin pamoate) | 1/17/2018 |
| Triptans | 1/17/2018 |
| VFEND® (voriconazole) | 1/17/2018 |
| Vancomycin Oral Compound Solution | 1/17/2018 |
| Vectibix® (panitumumab) | 1/17/2018 |
| Vimizim® (elosulfase alfa) | 1/17/2018 |
| Viscosupplements (Durolane®, Euflexxa®, Gel-One®, Gelsyn-3™, GenVisc® 850, Hyalgan®, Hymovis®, Supartz™, Supartz FX™, Synvisc®, Synvisc-One®, Visco-3™) | 1/17/2018 |
| Votrient® (pazopanib) | 1/17/2018 |
| Vraylar™ (cariprazine) | 1/17/2018 |
| Vyvanse® (lisdexamfetamine dimesylate) | 1/17/2018 |
| Xeljanz® and Xeljanz XR® (tofacitinib) | 1/17/2018 |
| Xeomin® (Botulinum Toxin) | 1/17/2018 |
| Xuriden™ (uridine triacetate) | 1/17/2018 |
| Zaltrap® (ziv-aflibercept) | 1/17/2018 |
| Zinplava™ (bezlotoxumab) | 1/17/2018 |
| Zoladex® (goserelin) | 1/17/2018 |
| Zostavax® (zoster vaccine live) | 1/17/2018 |
| Zuplenz® (ondansetron oral soluble film) | 1/17/2018 |
| Prandial and Intermediate Acting Insulins | 1/11/2018 |
| Qtern® (dapagliflozin and saxagliptin) | 1/4/2018 |
Click here to view the Humana Pharmacy Policy Updates »
Policy Alerts monitors Commercial and Medicare medical policies for changes. While Payers typically update medical policies annually, there are many reasons why a Payer might review or update a policy. When reviews occur out of cycle, they may go unnoticed. Policy Alerts keeps you informed of upcoming and unexpected coverage changes affecting your product. Quickly understanding the changes Payers make can help you adjust reimbursement strategies impacting your business.
Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on Payer decisions in real-time. Whenever changes occur, email notifications containing a summary of those changes are delivered to your inbox. Clients can access detailed coverage reports and medical policies on the interactive Dashboard portal. Save time and keep focused on the important Payer medical policy reviews and coverage decisions affecting your product!
Policy Alerts takes a client-focused hands-on approach and works hard to provide our customers with helpful insights and actionable analytics over raw data. We understand what our clients need and we are dedicated to making sure we provide timely, accurate and always up-to-date reports that can be used to implement and support a successful reimbursement strategy.
Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.
Related Posts
